Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 25;15(6):5231–5242. doi: 10.3892/etm.2018.6097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Prompunt et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Optimization of the cardioprotective dose of rhSLPI for ARVMs subjected to sI/R. ARVMs were cultured with various concentrations of rhSLPI and treated over three different periods, including (A and B) 2 h prior to sI, (C and D) at the onset of sI and (E and F) at the onset of reperfusion. Following rhSLPI treatment, all groups were subjected to 20 min sI followed by 2 h reperfusion. The percentage of viable cells and released LDH activity in all groups were determined. The results are presented as the mean ± standard error of the mean (n=3). *P<0.05 vs. control group; ^#P<0.05 vs. sI group. rhSLPI, recombinant human secretory leukocyte protease inhibitor; sI, stimulated ischemia; ARVM, adult rat ventricular myocytes; LDH, lactate dehydrogenase; sI/R, stimulated ischemia/reperfusion.